Compared with no medications for opioid use disorder, methadone and buprenorphine were each associated with decreased all-cause and opioid-related mortality.
Overall estimated prevalence of use of medications with depression as a potential adverse effect was 37.2%, increasing from 35.0% in 2005 and 2006 to 38.4% in 2013 and 2014.
A 56-year-old man is being evaluated after his 18-year-old son had a syncopal episode during a high school basketball game and was diagnosed with hypertrophic cardiomyopathy (HCM). The patient has had no symptoms, including with physical activity such as golfing or playing tennis. Findings of a comprehensive physical examination are unremarkable. An electrocardiogram and echocardiogram are normal, with no evidence of HCM. When should this patient next be screened for HCM?
Most effects were small and long-term evidence was sparse, and while there was no evidence suggesting serious harms from any of the interventions studied, data on harms were limited.
The case study examines if and under what conditions it may be ethically permissible to discuss deidentified information about a patient.
Philip Masters, MD, FACP, continues his monthly column at KevinMD.